MetaSight Diagnostics Overview
MetaSight develops and deploys accurate, affordable, and accessible diagnostics for diverse diseases through a single blood test – applicable for population scale screening. Its approach leverages the world’s largest clinico multi-OMICS database, generated using our proprietary unbiased metabolomics, lipidomics, and proteomics platform.
Cumulative Funding Raised Over Time ($)
—Apr 2022
$8.0MNov 2024
Latest News
growth-positive
MetaSight Diagnostics Raises $8M in Over-Subscribed Series A Funding Round
MetaSight Diagnostics, a health technology company based in Israel, has successfully closed an $8 million Series A financing round. The investment, led by new investors including aMoon Growth II Fund, Saban Ventures, ARC Ventures, and Alumni Ventures, will be used to advance MetaSights diagnostic programs into FDA trials and expand its product portfolio. The company, founded in 2021, specializes in multi-omics screening and diagnostic products for diseases such as colorectal cancer and metabolic dysfunction-associated steatohepatitis. MetaSight plans to use the funds to further develop its pipeline and engage in strategic partnerships, with the aim of making its tests available in selected markets by 2025.
InvestmentExpandPartners
growth-positive
פרופ' תומר שלומי הפעיל את המכונה קצת אחרת – וגילה קיצור דרך לבדיקות דם חדשות
MetaSight, a startup founded by Professor Tomer Shlomi from the Technion, has developed an algorithm that accelerates the analysis of blood samples using mass spectrometry. This innovation aims to make medical diagnostics more affordable and accessible to the general population. The company has successfully raised approximately $20 million in funding. Mass spectrometers, traditionally expensive and complex devices used in chemistry and biology labs, analyze the composition of blood samples, identifying proteins, fatty acids, and other molecules. Typically, each test takes about half an hour and costs several hundred dollars. MetaSights advancement could significantly reduce these costs and timeframes, potentially transforming the medical diagnostics industry.
Investment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $8M |
| Last funding | $8M |
| Stage | A |
| Rounds | 2 |
| Investors | 4 |
Team Members
2
Employees: 11-50
Web & Social Links
| Website | metasightdx.com |
Locations
Haim Holtsman St, Rehovot, Israel
Photos & Videos
No files yet
MetaSight Diagnostics Business
Business models
B2B
Product stage
R&D
Employees
11-50
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyTest Diagnostics & ScreeningTarget Customer
Healthcare & Life SciencesLife SciencesBiotechnologyPharmaceuticalsCore Technology
BiologicalsMoleculesTags (9)
spectroscopyoncologydiagnosticspharmaceuticalsbiopsybiotechnologyinflammatory-diseasesblood-testbiomarkersMetaSight Diagnostics Financials
$8M
Total funding
Undisclosed
Capital raised
$8M
Last funding
A
Funding stage
2
Total rounds
4
Investors
Cumulative Funding Raised Over Time ($)
—Apr 2022
$8.0MNov 2024
Private Equity Funding
A Round
Nov 2024
$8M
Saban Ventures, aMoon Fund, Alumni Ventures, Arc Ventures
Undisclosed Round
Apr 2022
Undisclosed
aMoon Fund (Lead)
MetaSight Diagnostics Lifecycle
Cumulative Funding Raised Over Time
—Apr 2022
$8.0MNov 2024
All Events
A Round
Nov 2024
$8M
Saban Ventures, aMoon Fund, Alumni Ventures, Arc Ventures
Undisclosed Round
Apr 2022
Undisclosed
aMoon Fund (Lead)
MetaSight Diagnostics News
2 articles
growth-positive
MetaSight Diagnostics Raises $8M in Over-Subscribed Series A Funding Round
MetaSight Diagnostics, a health technology company based in Israel, has successfully closed an $8 million Series A financing round. The investment, led by new investors including aMoon Growth II Fund, Saban Ventures, ARC Ventures, and Alumni Ventures, will be used to advance MetaSights diagnostic programs into FDA trials and expand its product portfolio. The company, founded in 2021, specializes in multi-omics screening and diagnostic products for diseases such as colorectal cancer and metabolic dysfunction-associated steatohepatitis. MetaSight plans to use the funds to further develop its pipeline and engage in strategic partnerships, with the aim of making its tests available in selected markets by 2025.
InvestmentExpandPartners
growth-positive
פרופ' תומר שלומי הפעיל את המכונה קצת אחרת – וגילה קיצור דרך לבדיקות דם חדשות
MetaSight, a startup founded by Professor Tomer Shlomi from the Technion, has developed an algorithm that accelerates the analysis of blood samples using mass spectrometry. This innovation aims to make medical diagnostics more affordable and accessible to the general population. The company has successfully raised approximately $20 million in funding. Mass spectrometers, traditionally expensive and complex devices used in chemistry and biology labs, analyze the composition of blood samples, identifying proteins, fatty acids, and other molecules. Typically, each test takes about half an hour and costs several hundred dollars. MetaSights advancement could significantly reduce these costs and timeframes, potentially transforming the medical diagnostics industry.
Investment
MetaSight Diagnostics Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 21 |
| Team members | 2 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 9 classification IDs that could be used for matching.
MetaSight Diagnostics Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 89/100 |
| Missing | video or image, markets, not claimed |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 516187796 |
| Creator | Yanina Wainscheinker |
| Creator email | yanina.wainscheinker@sncentral.org |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2024-11-14T00:00:00.000Z |
| Created | 2023-04-28T00:00:00.000Z |